ILMN Insider Trading

Insider Ownership Percentage: 0.17%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Illumina Insider Trading History Chart

This chart shows the insider buying and selling history at Illumina by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2M-$1M$0$1M$2MTotal Insider BuyingTotal Insider Selling

Illumina Share Price & Price History

Current Price: $80.00
Price Change: Price Decrease of -2.28 (-2.77%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for ILMN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$80.00Closing price on 03/29/25:

SEC Filings (Institutional Ownership Changes) for Illumina (NASDAQ:ILMN)

89.42% of Illumina stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ILMN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$2.36Bbought$959MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10B$0$10BTotal InflowsTotal Outflows
Illumina logo
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
Read More on Illumina

Today's Range

Now: $80.00
Low: $79.30
High: $82.35

50 Day Range

MA: $102.80
Low: $80.00
High: $141.31

52 Week Range

Now: $80.00
Low: $79.30
High: $156.66

Volume

1,526,373 shs

Average Volume

2,212,008 shs

Market Capitalization

$12.67 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17

Who are the company insiders with the largest holdings of Illumina?

Illumina's top insider investors include:
  1. Susan H Tousi (SVP)
  2. Jacob Thaysen (CEO)
  3. Aimee L Hoyt (SVP)
Learn More about top insider investors at Illumina.

Who are the major institutional investors of Illumina?

Illumina's top institutional investors include:
  1. Capital World Investors — 11.37%
  2. Vanguard Group Inc. — 9.97%
  3. Loomis Sayles & Co. L P — 2.65%
  4. WCM Investment Management LLC — 2.60%
  5. Bank of New York Mellon Corp — 2.15%
  6. Baillie Gifford & Co. — 1.90%
Learn More about top institutional investors of Illumina stock.

Which institutional investors are selling Illumina stock?

Within the last quarter, ILMN stock was sold by these institutional investors:
  1. Nuveen Asset Management LLC
  2. Two Sigma Advisers LP
  3. Baillie Gifford & Co.
  4. Alliancebernstein L.P.
  5. Corvex Management LP
  6. Ameriprise Financial Inc.
  7. Select Equity Group L.P.
  8. Invesco Ltd.

Which institutional investors are buying Illumina stock?

Within the previous quarter, ILMN stock was bought by institutional investors including:
  1. Capital World Investors
  2. Brown Advisory Inc.
  3. Norges Bank
  4. Bessemer Group Inc.
  5. WCM Investment Management LLC
  6. Pictet Asset Management Holding SA
  7. ARK Investment Management LLC
  8. Spyglass Capital Management LLC